Subscribe
shutterstock_607718810_vchal
vchal / Shutterstock.com
4 June 2019Genetics

Danish biotech company secures CRISPR licence

Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Charpentier granted new CRISPR/Cas9 patent
23 April 2019   ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
Charpentier granted new CRISPR/Cas9 patent
23 April 2019   ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.

More on this story

Americas
Charpentier granted new CRISPR/Cas9 patent
23 April 2019   ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court